Michael Campos, MD
Critical Care Medicine · Miami, FLNPI 1366489320
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by CSL Behring at 48.1% of the total. Reporting peaked in 2019 at $18,937 and has fallen 55.1% since, to $8,508 in 2025. Among critical care medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 71 payments — averaging $986.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$34K
- Grifols USA, LLC$13K
- Takeda Pharmaceuticals U.S.A., Inc.$10K
- Grifols Shared Services North America, Inc.$7K
- Chiesi USA, Inc.$4K
- AstraZeneca$1K
- plus $418 from 2 others
Across 90 payments — averaging $3912.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Grifols Therapeutics LLC$127K
- Astrazeneca UK Limited$66K
- Vertex$53K
- Grifols Biologicals LLC$48K
- Takeda Pharmaceuticals U.S.A., Inc.$20K
- Chiesi USA, Inc.$17K
- plus $21K from 2 others
What the payments were for
- Consulting fees$29,84443%
- Speaking & faculty fees$25,74137%
- Travel & lodging$11,99217%
- Food & beverage$2,4133%
- Education$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 17 | $33,716 |
| Grifols USA, LLC | 30 | $13,177 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $9,981 |
| Grifols Shared Services North America, Inc. | 6 | $7,185 |
| Chiesi USA, Inc. | 5 | $4,465 |
| AstraZeneca | 2 | $1,103 |
| Sanofi | 4 | $406 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Zemaira$33,494
- Prolastin-C Liquid$19,871
- GLASSIA$9,981
How this compares
$70,046 in reported general payments places this provider in the 95th percentile of 618 critical care medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GlassiaAlpha-1-Proteinase Inhibitor | 16 | $257,779 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 16 | $120,579 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $16,798 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $10,284 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $9,637 |
| Spiriva RespimatTiotropium Bromide | 13 | $8,912 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $7,982 |
| Fluticasone Propionate HfaFluticasone Propionate | 13 | $2,338 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $738 |
| Ventolin HfaAlbuterol Sulfate | 13 | $697 |
| Azelastine Hcl | 15 | $659 |
| Fluticasone Propionate | 19 | $427 |
| Azithromycin | 11 | $205 |
| Montelukast Sodium | 21 | $158 |
| Buspirone Hcl | 11 | $59 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $9,981 | $257,77916 claims |
| Grifols USA, LLCProlastin C | $13,177 | $120,57916 claims |
| AstraZenecaSymbicort | $1,103 | $10,28433 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 618 critical care medicine providers in Florida.
Other critical care medicine in Miami
- Alexandre AbreuMiami$34K
- Daniel KettMiami$14K
- Louis GuzziOrlando$635K
- Fortune AlabiKissimmee$587K
- Debabrata BandyopadhyayTampa$398K
- Fred UmehKissimmee$371K
- Amit TandonWesley Chapel$338K
- Omid ZadOrlando$325K
- Eddy GutierrezJacksonville$315K
- Maximo LamaKissimmee$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.